Trial Profile
BENEFIT 11 a Long-term Follow-up Study of the BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment, 304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis [EXTENSION of 700013650]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms BENEFIT-11
- Sponsors Bayer; Bayer HealthCare
- 16 Apr 2020 Results of 11-year follow-up of BENEFIT study assessing Vitamin D, smoking, EBV, and long-term cognitive performance in Multiple Sclerosis, published in the Neurology
- 15 Jun 2019 Trial has been completed in Spain, according to European Clinical Trials Database record.
- 10 Aug 2016 Results of a long term follow up for 11 years published in the Neurology.